A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Randomized, open label, multicenter, phase III Study of Entrectinib versus Crizotinib in patients with locally advanced of metastatic non-small lang cancer harboring ROS1 gene rearrangement with or without central nervous system metastases